After a ruling that the bill could not be passed through the reconciliation process, senators are scrambling to find another way to get the legislation before the president, who would veto it.
The Democratic presidential candidate laid out his health policy plan Tuesday in an effort to energize his struggling campaign.
NYC Health and Hospitals has named Plachikkat Anantharam to succeed Marlene Zurack as the system's chief financial officer.
Mark Newton will soon step down as president and CEO of Chicago's Swedish Covenant Hospital after leading the hospital for over 15 years. Chief Operating Officer Anthony Guaccio will replace him.
New York City will spend about $850 million over the next four years to improve mental-health services and expand access to care. The figure includes $305 million in new city spending on behavioral health.
Mississippi, which often leads the nation in its obesity rate, is proposing to pay for Medicaid beneficiaries' bariatric surgeries, according to state officials.
St. John's Hospital and insurer Horace Mann, both located in Springfield, Ill., will open a shared clinic for their employees in early 2016.
The U.S. Food and Drug Administration expects to release new guidance on a form of birth control that has been linked to more than 15,000 adverse events, including at least a dozen deaths, by the end of February.
Today's regional healthcare roundup includes a merger that creates the Denver area's largest primary-care doc group, New Jersey providers opposing a bill on out-of-network charges, the snub to hospitals in Florida Gov. Rick Scott's budget, and more.
Janet Corrigan, a former CEO of the National Quality Forum, has been appointed chief program officer for patient care at the Gordy and Betty Moore Foundation.
The CMS wants more information about the quality of care Medicare beneficiaries get in long-term-care hospitals, so the agency is preparing a new patient-satisfaction survey tailored to the facilities.
Pharmacy benefits manager CVS Health has included Amgen's drug Repatha to its formulary. The drug is one of two in a new class of cholesterol-lowering medications. It's the latest in a series of moves made by PBMs to address the high costs of some newer, brand-name therapies.